Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.48 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19827872 | 0.93 | ACHE (0.41) | ACHEPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL18061767 | 0.93 | ACHE (0.41) | ACHEPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL26026455 | 0.92 | ACHE (0.47) | ACHEPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL13030115 | 0.90 | ACHE (0.51) | ACHEPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10238971 | 0.90 | ACHE (0.39) | ACHEPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL15898757 | 0.90 | ACHE (0.39) | ACHEPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL15763413 | 0.88 | ACHE (0.38) | ACHEPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL15763458 | 0.88 | SLC29A1 (0.38) | ACHEPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL13030116 | 0.87 | NT5E (0.43) | PDE4APDE4BPDE4CPDE4DSLC29A1 | |
| SCHEMBL15850628 | 0.83 | PDE4A (0.49) | PDE4APDE4BPDE4CPDE4DSLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813278-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11738038-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-9045520-B2 | Synthesis of purine nucleosides | GILEAD PHARMASSET LLC (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045520-B2 | Synthesis of purine nucleosides | GILEAD PHARMASSET LLC (US) | 2015-06-02 | — | — | US | disclosed |
| US-8716263-B2 | Synthesis of purine nucleosides | GILEAD PHARMASSET LLC (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716263-B2 | Synthesis of purine nucleosides | GILEAD PHARMASSET LLC (US) | 2014-05-06 | — | — | US | disclosed |
| US-20120316327-A1 | SYNTHESIS OF PURINE NUCLEOSIDES | GILEAD PHARMASSET LLC (US) | 2012-12-13 | — | — | US | disclosed |
| US-20100279973-A1 | SYNTHESIS OF PURINE NUCLEOSIDES | PHARMASSET, INC. (US) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279973-A1 | SYNTHESIS OF PURINE NUCLEOSIDES | PNP, NUDT1, TYMP | ACHE 3086/4885PDE4A 271/4885PDE4B 317/4885 |
| US-20120316327-A1 | SYNTHESIS OF PURINE NUCLEOSIDES | PNP, NUDT1, TYMP | ACHE 3086/4885PDE4A 271/4885PDE4B 317/4885 |
| US-11813278-B2 | Highly active compounds against COVID-19 | PNP, ACE2, MTAP | ACHE 1045/4885PDE4A 1237/4885PDE4B 866/4885 |
| US-11738038-B2 | Highly active compounds against COVID-19 | PNP, ACE2, MTAP | ACHE 1045/4885PDE4A 1237/4885PDE4B 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.